Psoriasis is an immune-mediated, inflammatory condition of the skin affecting nearly 3 % of the world’s population. As a chronic disease psoriasis has a substantial effect on the quality of life of patients. More than 80% of patients have mild to moderate psoriasis, for which topical therapies are first line of treatment. Patients with severe psoriasis are eligible for systemic therapies (orals and biologics), which are often used in combination with topicals
Aim of MC2-01
For patients suffering from plaque psoriasis the dual mode of action of calcipotriene and betamethasone dipropionate (“Calcipotriene/BDP”) provides fast relief of symptoms with just once daily application, while offering a superior safety profile. BDP counteracts potential skin irritation of calcipotriene while calcipotriene mitigates potential skin atrophogenic effect of BDP. However, current marketed Calcipotriene/BDP formulations are greasy Vaseline-like or liquid oil formulations that many patients do not like to use, resulting in non-compliance and poor real-life efficacy.
PAD™ Technology uniquely enables a stable PAD™ cream formulation of Calcipotriene/BDP that quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on in daily routines. A single drug designed for both (i) rapid relief; (ii) longer term safety and (iii) patient satisfaction – a new treatment experience for patients with plaque psoriasis.
US Phase 3 is successfully completed – NDA in H1 2019.
EU Phase 3 ongoing – MAA in H2 2019.
MC2-01 PAD™ Cream
Active ingredients: Calcipotriene/betamethasone dipropionate
Indication: Plaque psoriasis